General
Preferred name
SORAFENIB
Synonyms
SORAFENIB TOSYLATE ()
BAY-43-9006 ()
BAY-439006, Nexavar ()
Sorafenib tosilate ()
[11C]-Sorafenib, Sorafenib Tosylate, BAY-54-9085, BAY-43-9006, Nexavar ()
BAY 43-9006 ()
BAY-439006 ()
NEXAVAR ()
BAY 43-9006 (free base) ()
BAY 54-9085 (tosylate salt) ()
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea ()
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide ()
SFN ()
CM-4307 ()
Sorafenib (Tosylate) ()
Bay 43-9006 (Tosylate) ()
Sorafenib (BAY 43-9006) tosylate ()
Sorafenib (BAY 43-9006) ()
Donafenib (Sorafenib D3) ()
BAY 43-9006 tosylate,NSC-724772 tosylate ()
NSC-724772,BAY 43-9006 ()
Bay 43-9006 D3, CM-4307 ()
BAY 54-9085 ()
BAY-54-9085 ()
donafenib ()
Sorafenib-d3 ()
P&D ID
PD003493
CAS
284461-73-0
475207-59-1
1130115-44-4
Tags
obsolete probe
probe
drug
natural product
drug candidate
available
Approved by
EMA
FDA
First approval
2005
Drug Status
investigational
approved
Drug indication
Renal cell carcinoma
Myelodysplastic syndrome
Hepatocellular carcinoma
Max Phase
Phase 4
Phase 3
Probe info
Probe type
calculated probe
Probe sources
Probe Miner (suitable probes)
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Sorafenib is a broad spectrum Type-2 kinase inhibitor targeting VEGFR2, VEGFR3, PDGFRβ, Flt3, and KIT and non-receptor kinases RAF1 and BRAF . (GtoPdb)
DESCRIPTION Donafenib (CM-4307) is a deuterated derivative of the approved multikinase inhibitor . Like sorafenib, it is orally active. Deuteration improves the stability of drug molecules thus extending half-life and increasing systemic exposure. This means that the effective drug dose may be shifted downward, with an associated improvement in tolerability. The medical formulation is donafenib tosylate. (GtoPdb)
DESCRIPTION Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. (PKIDB)
DESCRIPTION inhibitor of BRAF, CRAF, and VEGFR2 (Informer Set)
DESCRIPTION Potent and selective MEK inhibitor; orally bioavailable (Tocris Bioactive Compound Library)
Cell lines
353
Organisms
10
Compound Sets
38
AdooQ Bioactive Compound Library
A17857
A10001
Axon Medchem Screening Library
3351
1397
Cayman Chemical Bioactives
10009644
35612
34487
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1336
CHEMBL1200485
ChEMBL Drugs
CHEMBL1336
CHEMBL1200485
CHEMBL4297490
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
5711
Concise Guide to Pharmacology 2019/20
5711
Concise Guide to Pharmacology 2021/22
5711
Concise Guide to Pharmacology 2023/24
5711
Drug Repurposing Hub
DrugBank
DB00398
DB15414
DrugBank Approved Drugs
DB00398
DrugCentral
2459
DrugCentral Approved Drugs
2459
DrugMAP
DMS8IFC
DrugMAP Approved Drugs
DMS8IFC
Enamine BioReference Compounds
Guide to Pharmacology
5711
11830
Informer Set
349006
Ki Database
BAY-43-9006
LINCS compound set
10008-101
10008-104
10008-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1336
CHEMBL1200485
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1336
CHEMBL1200485
MedChem Express Bioactive Compound Library
HY-10201
HY-10201A
NCATS Inxight Approved Drugs
9ZOQ3TZI87
NIH Approved Oncology Drugs
91148447
NPC Screening Collection
Obsolete Compounds
sorafenib
PKIDB
Probe Miner (suitable probes)
P35968/885050
ReFrame library
Selleckchem Bioactive Compound Library
sorafenib
Sorafenib-Tosylate
donafenib-sorafenib-d3
TargetMol Bioactive Compound Library
T0093
Tocris Bioactive Compound Library
6814
Welcome Trust Cancer Drugs
30
ZINC Tool Compounds
ZINC000001493878
External IDs
81
Properties
(calculated by RDKit )
Molecular Weight
464.09
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
5.55
TPSA
92.35
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
3
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
BRAF
FLT3
KDR
RAF1
Serine/threonine-protein kinase B-raf
PDGFRA, PDGFRB, KDR, KIT, FLT3
Tyrosine-protein kinase receptor FLT3
Vascular endothelial growth factor receptor
Stem cell growth factor receptor
Platelet-derived growth factor receptor beta
Tyrosine-protein kinase receptor RET
Serine/threonine-protein kinase RAF
c-Kit
mPDGFR??
PDGFR??
b-RAF
B-Raf (V599E)
Raf-1
VEGFR2/Flk1
mPDGFR¦Â
PDGFR¦Â
VEGFR2/Flk2
BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET
Raf inhibitor
FLT4
PDGFRB
KIT
FGFR1
RET
FLT1
Ferroptosis
Apoptosis related,Autophagy,c-Kit,Ferroptosis,FGFR,FLT3,PDGFR,Raf,VEGFR
Apoptosis related,Autophagy,Ferroptosis,FLT3,PDGFR,Raf,VEGFR
Raf,VEGFR
Compound status
FDA
Pathway
RTK signaling
Angiogenesis
MAPK
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Apoptosis
Autophagy
MAPK/ERK Pathway
Protein Tyrosine Kinase/RTK
MOA
receptor protein-tyrosine kinase inhibitor
FLT
PDGFR
Raf
VEGFR
Inhibitor
FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor
Targets
RAF1,BRAF
Primary Target
Raf Kinases
Indication
renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)
Therapeutic Class
Anticancer Agents
Source data